Association for Molecular Pathology 2026

Join Foundation Medicine and expert faculty for a review of the evolving role of tissue-informed molecular residual disease (MRD) testing in breast cancer. This workshop will explore how circulating tumor DNA (ctDNA) can be used across the patient journey, from baseline assessment and postoperative surveillance to early detection of molecular recurrence. Faculty will discuss recent evidence, emerging applications, and key considerations for integrating tissue-informed MRD insights into patient management and clinical trial strategies. Attendees will gain perspective on the opportunities and challenges shaping the future of tissue-informed MRD-guided care in solid tumors.

Join Roche and Foundation Medicine for an educational workshop exploring the emerging role of HLA Class I typing within comprehensive genomic profiling (CGP). Participants will review the scientific rationale for HLA analysis, analytical performance data, and opportunities to integrate genomic and immunogenetic insights within a single testing workflow. The session will highlight applications in immuno-oncology research, including immune checkpoint inhibitors, neoantigen-based therapies, and adoptive cell therapies, while also discussing future directions for incorporating HLA typing into precision oncology and molecular testing workflows.

Transitioning complex molecular diagnostic assays to shelf-stable formats often forces workflow compromises or complex multi-vendor sourcing. Roche CustomBiotech addresses these challenges with a unified, lyo-ready reagent suite spanning from sample-to-answer.

Featuring our new high-concentration, glycerol-free Proteinase K* for sample preparation, this session details how to construct robust, ambient-stable assays from start to finish. We share performance data on integrating lyo-ready enzymes across sample prep, reverse transcription, and amplification. Discover how an end-to-end lyo-ready ecosystem helps minimize cold-chain friction, streamline development, and simplify scale-up for IVD applications.

*For further processing only.

Learn how EuroClonality-NDC and Myeloid-NDC NGS Workflows are utilized in advancing the research into the future of diagnostics, prognostics, and targeted therapies and how these revolutionary assays provide comprehensive genomic data that reveals mutations, structural variations, and clonal evolution patterns with remarkable resolution, enabling clinical researchers to delve deeper into the genomic landscape of hematological malignancies.  

For Research Use Only. Not for use in diagnostic procedures.

High-Sensitivity Whole Genomic Profiling of Circulating Tumor Cells Using the AXELIOS 1 Platform

Francois Aguet and Julian Hess from Predicta Biosciences will highlight a study demonstrating how Roche’s AXELIOS 1 sequencing platform delivers the speed, throughput, and low cost needed for longitudinal genomic research. By combining Predicta’s ultrasensitive GenoPredicta assay and proprietary bioinformatics with AXELIOS 1’s long simplex reads, the pipeline achieves high-quality, deep whole genome profiling from circulating tumor cells. This approach provides a highly sensitive, cost-effective solution for comprehensive molecular characterization and minimal residual disease (MRD) research in multiple myeloma.

Twist Bioscience’s targeted enrichment solution for AXELIOS 1

Twist Bioscience is pleased to introduce target enrichment solutions optimized specifically for the AXELIOS 1 Platform's transformative high-throughput sequencing technology. Through a strategic collaboration with Roche, the offering pairs the speed and flexibility of the AXELIOS 1 with Twist’s leading enrichment technology, featuring rapid panel customization, optimized target capture, and reliable performance across targeted sequencing workflows. By uniting the AXELIOS 1 sequencing architecture and library prep with Twist’s target enrichment, the solution aims to streamline sequencing efficiency for complex somatic NGS research. Here we share early data from our collaboration with Twist, highlighting key performance features, data quality metrics, and operational advantages.

For Research Use Only. Not for use in diagnostic procedures. AXELIOS is a trademark of Roche.
The technology is capable of generating longer reads of up to ~1500bp (with a distribution from ~200bp to ~1500 bp) under appropriate sample and library prep conditions.

Identifying pathogenic germline variants is foundational to researching hereditary cancer syndromes and Mendelian disorders.  However, moving from DNA through raw sequencing data to a causative variant is a complex challenge.  It requires high-efficiency sample preparation and whole-exome sequencing (WES), robust yet accessible secondary analysis, and sophisticated phenotype-driven tertiary analysis.  First we will discuss integrated, end-to-end workflows — including either Roche’s AXELIOS 1 platform or another sequencer — for leveraging phenotypic data to identify pathogenic variants in research samples. In the second half, we will investigate two complementary approaches for identifying relevant RNA Fusions in research samples:  Whole Transcriptome RNA-Sequencing and Exome-targeted RNA-Sequencing.

For Research Use Only. Not for use in diagnostic procedures. AXELIOS is a trademark of Roche.